Elixion Biotech takes quantum-informed R&D route for next-gen precision medicines

Elixion Biotech has announced the successful in-silico validation of five therapeutic targets through its pioneering quantum physics–informed drug discovery platform.

This milestone confirms the predictive strength of Elixion’s R&D approach and marks a major step toward accelerating precision medicine development. Completed within just eleven months and entirely self-funded, the achievement underscores Elixion’s mission to bring transformative treatments to patients faster and more efficiently.

Elixion’s first validation program focused on breast cancer, one of the most prevalent and deadly forms of cancer worldwide. Within this area, HER2-negative and triple-negative breast cancers (TNBC) represent significant unmet clinical needs due to their complexity and limited treatment options. Elixion’s quantum-informed process successfully recovered well-established biomarkers such as HER2/ERBB2, ESR1, BRCA1, and BRCA2, while also identifying new, clinically relevant therapeutic targets and molecular pathways that have remained undetected using conventional methods.

“This is more than a technical milestone—it’s proof that our process works,” said Marco Piccinini, Co-Founder and CEO of Elixion Biotech. “We’ve demonstrated that our quantum-informed approach can uncover meaningful targets with real potential to become tomorrow’s medicines. With this validation, we’re ready to move from stealth to scale and from prediction to preclinical development.”

Elixion’s R&D platform integrates quantum physics, causal biology, multi-omics, and native AI to achieve unprecedented precision and efficiency in early-stage drug discovery. By leveraging quantum mechanics to interpret biological complexity at the molecular level, Elixion can identify promising targets faster, design safer and more effective compounds, and reduce the costly trial-and-error typically associated with drug development.

This innovative model combines scientific depth with commercial discipline, enabling faster decision-making, lower attrition rates, and a clearer path from discovery to clinical readiness. 

With in-silicovalidation complete, Elixion is now advancing toward wet-lab validation and preclinical translation, moving its newly validated targets into compound design and functional studies. Following a successful self-funded pre-seed stage, the company is opening its seed round to accelerate the growth of its precision oncology pipeline and bring its next generation of quantum-informed therapies closer to patients.